Market leadership USP Zdrowie is a leading OTC and medicines player in Poland with a portfolio of top Polish brands such as Apap, Ibuprom, Gripex, Verdin, Stoperan, and Xenna, suggesting strong consumer trust and potential for cross-sell of related healthcare products.

Financial scale With annual revenue in the 50 to 100 million USD range and a headcount of roughly 500–1,000 employees, the company demonstrates solid market presence and potential for larger regional supplier contracts, co-branding, or private-label opportunities.

Expansion signals Recent activity around new product packaging (Highp package) indicates a willingness to innovate and diversify offerings, presenting opportunities to discuss new product launches, reformulations, or packaging collaborations.

Digital and tech Usage of multiple tech tools (Azure DevOps, Microsoft Teams, R Project, data-oriented workflows) suggests openness to data-driven partnerships, ERP/CRM integrations, and collaborative sales or marketing automation initiatives.

Strategic positioning As part of the USP Group and a premier Polish OTC brand lineup, there is potential to explore distribution partnerships, co-promotional campaigns, or entry points for international suppliers seeking access to the Polish market through a trusted local leader.